Invokana Lawsuit Emerges in Part from ISMP Reports Connecting Side Effects with 168 Reports of Metabolic Acidosis

April 30, 2016 – – TheProductLawyers.com reports that, in the last year, 5,500 adverse events involving Invokana have been reported to the FDA and reviewed by the Institute for Safe Medication Practices (ISMP) in their report QuarterWatch. Of these adverse events, ISMP identified more than 150 that involve new-generation drug Invokana, used to treat type 2 diabetes, and patients who developed metabolic acidosis, the buildup of toxic acid in the blood which is potentially life-threatening.

The medication which is the subject of these reports, Invokana, helps lower blood glucose (sugar) levels in type 2 diabetes patients by causing the sugar to be eliminated from the body by urination. It is one of several in a class of diabetes drugs released called SGLT2 inhibitors. While adverse event reports have been filed for all drugs in this class, Invokana is both the first released for use, and currently the SGLT2 with the most diabetic ketoacidosis event reports.

In May 2015, the U.S. Food and Drug Administration (FDA) released a drug safety announcement concerning the potential for elevated acid levels in the blood related to Invokana. The announcement was updated in December of 2015, and now includes potentially fatal urinary tract infection and diabetic ketoacidosis risks and a requirement for updated labeling information. The FDA has required Janssen Pharmaceuticals, the manufacturer of Invokana whose parent company is industry giant Johnson & Johnson, to update the drug’s labeling to include a better declaration of the known potential risks.

Sponsors of online resource TheProductLawyers.com, a website focused on presenting information to the public about Invokana and other drugs, the attorneys with Banville Law are engaged in helping those whose use of Invokana may have resulted in health problems. Patients who have taken SGLT2 inhibitor class medications, including Invokana, and experienced adverse events which they attribute to the drug may be entitled to substantial compensation. Banville Law offers legal consultations for free to qualifying parties, helping them to pursue the opportunity to investigate and understand their legal rights.

For more information about the Invokana lawsuits, or this press release, please contact TheProductLawyers.com on 888-997-3792.

###

Contact TheProductLawyers.com:

Banville Law
888-997-3792
info@banvillelaw.com
165 West End Ave #1h,
New York, NY 10023

ReleaseID: 60009595